Site Search
Professionals 149 results
Capabilities 35 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
Our Patent Litigation Practice is one of the country’s most active and highly regarded. Our seasoned patent litigators bring extensive courtroom experience to every matter we handle. According to Lex Machina, we are among the top three national patent defense firms in the country for number of appearances and cases filed, and we also were the top national defense firm for number of patent trials in the last five years (2018–2022).
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Experience 18 results
Experience
|February 12, 2024
Insights & News 336 results
Client Alert
|July 7, 2025
|4 Min Read
On June 11, 2025, Assistant Attorney General Brett Shumate issued a memorandum to all U.S. Department of Justice Civil Division employees outlining enforcement priorities under directives from President Trump and Attorney General Bondi. The Memorandum signals a shift in federal enforcement focus to issues such as discrimination, gender transition care, and immigration, and identifies the False Claims Act as a tool to achieve certain of the Administration’s goals.
In the Media
|June 25, 2025
|2 Min Read
Conor Reidy Discusses New Antitrust Law in Washington State with Private Funds CFO
Winston & Strawn partner Conor Reidy spoke with Private Funds CFO to discuss the first-of-its-kind antitrust law in Washington state and what this means for private fund managers. Under the new law, which will take effect July 27, any company required to file for Federal Trade Commission merger review under the Hart-Scott-Rodino Act that does sufficient business in Washington must also file for review with Washington’s attorney general. Firms will have to file in Washington if their principal place of business is in Washington, if the in-state value of the merger is at least 20 percent of the federal Hart-Scott threshold, or if at least one firm’s annual net sales in Washington reach 20 percent of the federal threshold.
Press Release
|June 24, 2025
|1 Min Read
Winston & Strawn Expands Restructuring Practice with Addition of Jonathan Levine in New York
NEW YORK – June 24, 2025 – Winston & Strawn LLP announced today that Jonathan Levine has joined its New York office as a partner in the firm’s Transactions Department and a member of the Restructuring Practice.
Other Results 27 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Law Glossary
How Does an Applicant Establish Biosimilarity?
An applicant typically demonstrates biosimilarity based on non-clinical analyses that focus on the structure and functional differences between the biosimilar and reference product.